Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance

JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.

Earnings Data Deluge

Earnings Data Deluge.

Mark Vickery headshot

Q3 Earnings Beats: C, GS, BAC, JNJ, WBA; Empire State Lower

While Goldman Sachs (GS) and Citi (C) both impressed on earnings this morning, Walgreens (WBA) looks to bounce back.

Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.01% and 1.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Q3 Earnings Results of U.S. Corporate Giants in Focus

Q3 Earnings Results of U.S. Corporate Giants in Focus.

Mark Vickery headshot

Bank Holiday Ahead of Busy Stock Trading Week

Despite today's day off from econ metrics, we see a pretty busy week ahead.

Johnson & Johnson (JNJ) Stock Moves -0.09%: What You Should Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.51, denoting a -0.09% change from the preceding trading day.

Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?

ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

Smart Beta ETF report for PWV

Derek Lewis headshot

Should Investors Consider High Yield Dividend Stocks?

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But is high yield always the way to go?

Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.

Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus

As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.

Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today

Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.

Kinjel Shah headshot

J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.

Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.